MedTrace Logo

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

NCT05233410 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-11-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

Conditions

  • Chronic Hand Eczema (CHE)

Interventions

DRUG

Ruxolitinib cream

Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

DRUG

Vehicle

Vehicle cream is a topical formulation applied as a thin film to affected areas.

Sponsors & Collaborators

Principal Investigators

  • Haq Nawaz, MD · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2024-04-25
Completion
2024-09-22
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05233410 on ClinicalTrials.gov